MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why MCRB Stock surged +8.94% Today — RQD Quant Desk Flash
$1.95 +8.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.98
Seres Therapeutics Inc. (MCRB) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $19.6M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.98 (+1.42%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 86.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-2.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MCRB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY MCRB SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (22% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)
Capital intensity & 0% operating margin leave 12 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$2.71-9.2% Next Q
62
Q2 (-2Q)Grade C$2.46-15% Next Q
59
Q3 (-1Q)Grade C$2.09-6.7% Next Q
57
CurrentGrade D+$1.95-0.7% Hist 90D α
54
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MCRB Turnaround Squeeze
While MCRB currently carries a cautious 54/100 (D+) rating due to Cash Engine Quality (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.62) and Max Pain ($2.05) forces dealer call-delta covering toward $31.48.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.68% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MCRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MCRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MCRB Stock surged +8.94% Today — RQD Quant Desk Flash
Seres Therapeutics Inc. (MCRB) surged +8.94% to $1.95, trading at 2% of its 52-week range ($1.68 – $29.98). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.68 – $29.98) with RSI-14 at 20.9 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $865000 annual free cash flow.
Live MCRB Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MCRB)
- ✓Walkthrough of MCRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MCRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.54%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.92H $1.95L $1.75C $1.95VOL 120.1K
RES: $3.76SUP: $1.56SMA50: $3.62SMA200: $7.11
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MCRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MCRB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MCRB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MCRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MCRB)
Health Care Rank #296 of 1016
⚔️ QNRX vs MCRB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MCRB vs. QNRX, KPTI, PBM, COCP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Seres Therapeutics Inc. (MCRB) ranks #296 by composite RQD confidence (54/100, grade D+) and #836 by equity capitalization ($19.6M). Within this direct 5-issuer industry benchmark cohort, MCRB leads on earnings valuation at N/A trailing P/E, while MCRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with MCRB at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MCRB
ACTIVE
Seres Therapeutics Inc. | D+ | 54/100 | — | — | -35.0% | +8.94% | $19.6M | Benchmark Subject |
| QNRX Quoin Pharmaceuticals Ltd. | D | 48/100 | — | — | -35.0% | +0.97% | $19.9M | /qnrx-vs-mcrb → |
| KPTI Karyopharm Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +5.73% | $20.0M | /kpti-vs-mcrb → |
| PBM Psyence Biomedical Ltd. | C- | 61/100 | — | — | — | +6.18% | $19.2M | /pbm-vs-mcrb → |
| COCP Cocrystal Pharma Inc. | D- | 42/100 | — | — | -35.0% | -1.01% | $18.9M | /cocp-vs-mcrb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001609809In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seres Therapeutics Inc. (MCRB) reported GAAP revenue of $789.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $5.7M, operating cash flow of $1.1M, and free cash flow of $865.0K (+100.6% YoY). On the balance sheet, MCRB closed FY2025 with $138.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $789.0K | $5.7M | $1.1M | $865.0K | $138.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $136.0K | -$148.6M | -$149.0M | $139.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$113.7M | -$117.4M | -$117.4M | — | — |
3. MCRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MCRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Seres Therapeutics Inc. (NASDAQ: MCRB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.95 (+8.94% 1D, market cap $19.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, MCRB ranks #296 in composite RQD confidence.
How does MCRB compare to QNRX and KPTI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MCRB carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $19.9M) and KPTI (Karyopharm Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $20.0M). Among the 5-stock peer group, MCRB leads on earnings multiple (N/A) while MCRB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MCRB?
Per MCRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609809), Seres Therapeutics Inc. generated $789.0K in revenue, $5.7M in net income, and $865.0K in free cash flow against $138.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MCRB trading relative to its 50-day, 200-day, and 52-week technical levels?
MCRB last traded at $1.95 (+8.94% on volume of 78,506 shares), positioning the stock -46.13% below its 50-day simple moving average ($3.62) and -72.57% below its 200-day simple moving average ($7.11). Across its 52-week range of $1.68 to $29.98, MCRB sits at the 1.0% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.71 to $2.19).
MCRB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MCRB stock moving today?
Why MCRB Stock surged +8.94% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.